REPORT OVERVIEW
-
Request a Free Sample to learn more about this report
The global Japanese encephalitis vaccine market size was 220.9 million in 2022. As per our research, the market is expected to reach USD 300.3 million by 2028, exhibiting a CAGR of 5.3% during the forecast period. The COVID-19 pandemic has been unprecedented and staggering, with Japanese encephalitis vaccine experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.
The Japanese encephalitis virus (JEV) vaccine guards against Japanese encephalitis, a serious brain infection transmitted by mosquitoes, particularly the Culex species. The vaccine options include inactivated Vero cell-derived vaccines and live attenuated SA 14-14-2 vaccines, with the latter used primarily in China. A chimeric virus vaccine, combining Japanese encephalitis and yellow fever genes, is also available. Vaccination schedules vary based on the vaccine and recipient's factors.
Before traveling to high-risk areas, seeking advice from healthcare professionals is crucial to determine the vaccine's suitability, as side effects and contraindications can arise. In essence, the Japanese encephalitis virus vaccine is a crucial tool to prevent the spread of a brain infection caused by mosquitoes. Available in various formulations, its administration depends on factors such as location and personal health. Consulting healthcare experts prior to travel is essential due to potential adverse effects and suitability concerns.
COVID-19 IMPACT : Disruption of Healthcare Services to Hamper Demand Significantly
COVID-19 had a life changing impact globally. The Japanese encephalitis vaccine market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for Japanese encephalitis vaccine experienced a reduced demand.
The production and distribution of vaccines can be affected by disruptions in the supply chain, transportation challenges, and redirection of resources towards pandemic-related efforts. This could indirectly impact the availability of Japanese encephalitis vaccines in certain regions. During a pandemic, public health messaging and communication efforts might be concentrated on the pandemic itself, potentially leading to decreased awareness about other diseases and vaccinations. This could result in decreased demand for Japanese encephalitis vaccination services.
During a pandemic, healthcare systems may be overwhelmed, and resources could be redirected to managing the pandemic. This might result in reduced access to routine vaccination programs, including those for Japanese encephalitis. People's reluctance or inability to visit healthcare facilities during a pandemic can also lead to missed vaccinations, potentially leaving populations vulnerable to diseases like Japanese encephalitis.
LATEST TRENDS
"Research on Vaccine Effectiveness to Broaden Market Growth"
Researchers continuously strive to improve vaccine formulations, including making them more immunogenic, cost-effective, and easier to administer. Advances in vaccine technology might lead to the development of vaccines with improved characteristics. Continued research could focus on evaluating the long-term effectiveness of existing vaccines, assessing the need for booster doses, and identifying populations that might benefit from vaccination.
The use of JEV vaccines in regions where the virus is endemic may have expanded, driven by increased awareness, infrastructure improvements, and public health initiatives. There might be ongoing efforts to develop combination vaccines that protect against multiple diseases, including Japanese encephalitis. Combining vaccines can improve vaccination coverage and efficiency. These latest developments are anticipated to boost the Japanese encephalitis vaccine market growth.
SEGMENTATION
-
Request a Free Sample to learn more about this report
- By Type
Based on type, the market is divided into Inactivated Vaccine and Live Attenuated Vaccine.
Inactivated Vaccine holds a major share of the global market.
- By Application
Based on application, the market is bifurcated into Public and Private.
Public as application holds a major share of the global market.
DRIVING FACTORS
"Global Health Initiatives to Boost Market Share"
International health organizations, such as the World Health Organization (WHO), emphasize the importance of vaccines to achieve global health goals. This support contributes to the availability of JEV vaccines in affected regions. Advances in vaccine technology, formulation, and production have made it possible to develop vaccines that are safer, more effective, and easier to distribute, thereby increasing the feasibility of JEV vaccine development.
"Public Awareness to Boost Market Size"
Education and awareness campaigns play a role in increasing demand for the vaccine by informing communities about the risks of Japanese encephalitis and the benefits of vaccination. Japanese encephalitis is endemic in many countries in Asia and the Western Pacific. The presence of the virus in these regions drives the demand for vaccination as a preventive measure among both local populations and travelers. These factors are anticipated to drive the growth of Japanese encephalitis vaccine market.
RESTRAINING FACTORS
"Complexity of Disease Transmission to Hamper Market Share"
The transmission of Japanese encephalitis virus involves complex interactions between the virus, mosquito vectors, and vertebrate hosts. This complexity can make it challenging to implement effective control strategies, including vaccination. Ensuring access to vaccines, especially in low-income and remote areas, can be difficult due to issues such as distribution challenges, lack of healthcare infrastructure, and affordability concerns. The factors are anticipated to hinder the growth of this market.
REGIONAL INSIGHTS
-
Request a Free Sample to learn more about this report
"Asia Pacific to Dominate the Market Owing to Development in Healthcare System"
Asia Pacific is the major shareholder for the Japanese encephalitis vaccine market share. Historically, the countries in Asia and the Western Pacific region, where Japanese encephalitis is endemic, have had a significant interest in the development and distribution of the JEV vaccine. These countries include parts of South and Southeast Asia, East Asia, and the Pacific Islands. The JEV vaccine is a critical tool for preventing the spread of the disease in these regions due to the higher risk of exposure to the virus.
KEY INDUSTRY PLAYERS
"Key Players Focus on Partnerships to Gain a Competitive Advantage "
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.
List of Market Players Profiled
- Research Foundation for Microbial Diseases of Osaka University [Japan]
- Valneva Austria GmbH [Austria]
- Chengdu Institute of Biological Products Co., Ltd. [China]
- Liaoning Cheng Da Biotechnology Co., Ltd. (Liaoning Dacheng) [China]
- Wuhan Institute of Biological Products Co., Ltd [China]
REPORT COVERAGE
This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 220.9 Million in 2022 |
Market Size Value By |
US$ 300.3 Million by 2028 |
Growth Rate |
CAGR of 5.3% from 2022 to 2028 |
Forecast Period |
2022-2028 |
Base Year |
2022 |
Historical Data Available |
Yes |
Segments Covered |
Type and Application |
Regional Scope |
Global |
Frequently Asked Questions
-
What value is the Japanese encephalitis vaccine market expected to touch by 2028?
The global Japanese encephalitis vaccine market is expected to reach USD 300.3 million by 2028.
-
What CAGR is the Japanese encephalitis vaccine market expected to exhibit by 2028?
The Japanese encephalitis vaccine market is expected to exhibit a CAGR of 5.3% by 2028.
-
Which are the driving factors of the Japanese encephalitis vaccine market?
Global Health Initiatives and Public Awareness are drivers of this Japanese encephalitis vaccine market.
-
Which are the top companies operating in the Japanese encephalitis vaccine market?
Research Foundation for Microbial Diseases of Osaka University, Valneva Austria GmbH, Chengdu Institute of Biological Products Co., Ltd, Liaoning Cheng Da Biotechnology Co., Ltd. (Liaoning Dacheng) and Wuhan Institute of Biological Products Co., Ltd are key companies operating in the Japanese encephalitis vaccine market.